Cartesian Therapeutics, Inc. (NASDAQ:RNAC – Get Free Report) CTO Metin Kurtoglu sold 34,400 shares of the company’s stock in a transaction on Monday, November 18th. The stock was sold at an average price of $18.39, for a total value of $632,616.00. Following the sale, the chief technology officer now owns 51,033 shares of the company’s stock, valued at approximately $938,496.87. This represents a 40.27 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.
Metin Kurtoglu also recently made the following trade(s):
- On Thursday, November 14th, Metin Kurtoglu sold 25,900 shares of Cartesian Therapeutics stock. The stock was sold at an average price of $16.44, for a total value of $425,796.00.
Cartesian Therapeutics Stock Down 3.5 %
Shares of NASDAQ:RNAC opened at $16.94 on Thursday. The firm has a market cap of $430.61 million, a P/E ratio of -0.33 and a beta of 0.63. Cartesian Therapeutics, Inc. has a 12-month low of $11.66 and a 12-month high of $42.60. The business has a fifty day simple moving average of $19.42 and a 200 day simple moving average of $20.13.
Wall Street Analyst Weigh In
Get Our Latest Analysis on Cartesian Therapeutics
Hedge Funds Weigh In On Cartesian Therapeutics
A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. BNP Paribas Financial Markets grew its holdings in Cartesian Therapeutics by 122.5% during the 3rd quarter. BNP Paribas Financial Markets now owns 1,651 shares of the company’s stock worth $27,000 after acquiring an additional 909 shares during the period. SG Americas Securities LLC bought a new stake in shares of Cartesian Therapeutics during the first quarter worth about $31,000. American International Group Inc. bought a new stake in Cartesian Therapeutics during the 1st quarter worth approximately $37,000. Point72 DIFC Ltd purchased a new stake in shares of Cartesian Therapeutics in the second quarter valued at about $47,000. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Cartesian Therapeutics in the 2nd quarter worth approximately $49,000. 86.95% of the stock is owned by institutional investors and hedge funds.
Cartesian Therapeutics Company Profile
Cartesian Therapeutics, Inc, a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases.
Recommended Stories
- Five stocks we like better than Cartesian Therapeutics
- Most active stocks: Dollar volume vs share volume
- Target Results Are Not a Retail Bellwether: Why the Dip Is a Buy
- 3 Tickers Leading a Meme Stock Revival
- Williams-Sonoma Stock: Buy It and Never Let It Go
- 3 Small Caps With Big Return Potential
- 5 Dividend ETFs to Buy and Hold Forever
Receive News & Ratings for Cartesian Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cartesian Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.